Lycia Therapeutics director reports 89,781 shares

The option awards vest in additional monthly 1/48 increments, subject to service on each vesting date.

Rhea-AI Filing Summary

Lycia Therapeutics, Inc. director William Jl Rieflin reported holdings dated October 22, 2026, including 89,781 common shares held by the William J. Rieflin 2026 GRAT; Rieflin is the trust’s beneficiary and sole trustee. He also reported two direct stock options covering 34,377 and 24,840 common shares, with exercise prices of $2.44 and $3.70 and expiration dates of June 27, 2034, and August 10, 2036, respectively. Each option award vested as to 1/48 on its stated initial vesting date, with an additional 1/48 vesting monthly thereafter, subject to service on each vesting date.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider RIEFLIN WILLIAM JL

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy) F2	--	--	--
holding	Stock Option (Right to Buy) F3	--	--	--
holding	Common Stock F1	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 59,217 contracts (Direct); Common Stock — 89,781 shares (Indirect, By Trust)

Footnotes (3)

1. F1. These securities are held by the William J. Rieflin 2026 GRAT Dtd 9/30/26 of which the Reporting Person is beneficiary and sole trustee.
2. F2. The options vested as to 1/48 of the total award on July 27, 2024, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
3. F3. The options vested as to 1/48 of the total award on September 6, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Common shares held by trust: 89,781 shares Option underlying shares: 34,377 shares Exercise price: $2.44 per share +2 more

5 metrics

Common shares held by trust 89,781 shares Reported October 22, 2026

Option underlying shares 34,377 shares Direct stock option; expires June 27, 2034

Exercise price $2.44 per share Direct stock option expiring June 27, 2034

Option underlying shares 24,840 shares Direct stock option; expires August 10, 2036

Exercise price $3.70 per share Direct stock option expiring August 10, 2036

Key Terms

Stock Option (Right to Buy), vested, GRAT

3 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

vested financial

"options vested as to 1/48 of the total award"

GRAT financial

"William J. Rieflin 2026 GRAT"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LYCA shares did William Jl Rieflin report holding?

William Jl Rieflin reported 89,781 Lycia Therapeutics common shares held by the William J. Rieflin 2026 GRAT. He is identified as the trust’s beneficiary and sole trustee.

What stock options did William Jl Rieflin report for LYCA?

Rieflin reported direct options covering 34,377 shares at an exercise price of $2.44, expiring June 27, 2034, and 24,840 shares at $3.70, expiring August 10, 2036. Each award vests in monthly 1/48 increments after its stated initial vesting, subject to service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/24/2026 - 08:15 PM EDT Accepted by SEC EDGAR 10/22/2026 - 07:18 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

RIEFLIN WILLIAM JL

(Last) (First) (Middle)

C/O LYCIA THERAPEUTICS, INC.

400 EAST JAMIE COURT, SUITE 200

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/22/2026

3. Issuer Name and Ticker or Trading Symbol
Lycia Therapeutics, Inc. [ LYCA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	89,781	I	By Trust(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	06/27/2034	Common Stock	34,377	$2.44	D
Stock Option (Right to Buy)	(3)	08/10/2036	Common Stock	24,840	$3.7	D

Explanation of Responses:

1. These securities are held by the William J. Rieflin 2026 GRAT Dtd 9/30/26 of which the Reporting Person is beneficiary and sole trustee.

2. The options vested as to 1/48 of the total award on July 27, 2024, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

3. The options vested as to 1/48 of the total award on September 6, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Amy Bachrodt, Attorney-in-Fact	10/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)